12 Jun 2024
What a day to remember!
The 16th International @AegeanConf Conference on #ComplementTherapeutics is dedicated to the pioneering work and groundbreaking contributions of @LambrisJD to #complementbiology & drug discovery #compstatins
Happy 70th John!! What an inspiring journey!
1
4
26
921
31 May 2024
Translating research results into tangible therapies that can change patients' lives to the better....is at the core of our research endeavors. So glad to have been able to witness the full-fledged transformation of compstatins from therapeutic leads to clinically approved therapies! pennmedicine.org/news/public…
3
15
904
18 Feb 2023
Elated to see our 2nd gen compstatin-based C3 inhibitor find its way to patients with GA, an inflammatory ocular disease with such a huge burden! Remarkable news and a great thrust to continue improving compstatins! investors.apellis.com/news-r…
8
30
2,978
2 Nov 2022
Scientists from @UniBasel_en, @PennMedicine, @UniLeipzig and @UniUtrecht provide molecular insights into the mode-of-action of the compstatin family of complement inhibitors. #compstatins, #therapeutics
@RicklinLab, @LambrisJD and @ChristinaLamers
go.nature.com/3sMfjjP
8
9
18 Jun 2022
Antonio Risitano in a tour-de-force of how the #PNH #hematology field was reshaped over the last 15 ys advancing from anti-C5 therapy to #C3-targeted inhibition w/ #compstatins
History in the making...
14th International @AegeanConf of #ComplementTherapeutics #Rhodes
8
13 Apr 2022
Insightful comment by Karpman, Bekassy, @palheox & @roumenina on the prospects of therapeutic complement #C3 inhibition in #AMR and kidney #transplantation #ComplementTherapeutics #compstatins
nature.com/articles/s41423-0…
2
6
9
Compstatins: the dawn of clinical C3-targeted complement inhibition, online now, review article from Christina Lamers, Dimitrios C. Mastellos, Daniel Ricklin and John D. Lambris. @ChristinaLamers @dmastellos @LambrisJD @NCSR_Demokritos @PennPathLabMed cell.com/trends/pharmacologi…
8
10
25 Jan 2022
The approval of #pegcetacoplan, a 2nd gen compstatin-based C3 inhibitor in 2021 serves as critical validation of C3-targeted treatment. This review traces the #evolution of compstatins from their academic 'roots' to the clinic and highlights current and future clinical directions
5
25 Jan 2022
Our latest review on the #compstatin class of clinical #C3 inhibitors now out @TrendsinPharma! With insights on #structure-#activity, #mode of action #PK/#PD aspects & the emerging therapeutic potential of #compstatins in chronic neurodegenerative diseases
sciencedirect.com/science/ar…
1
5
15
12 Jan 2022
The first heart #xenotransplantation is a game-changer! Back in 1999 we showed with Tom Mollnes that #compstatins can block hyperacute #rejection prolonging survival of perfused pig #xenograft Later on this effect was recapitulated in pig hearts w/ Cp40!
ncbi.nlm.nih.gov/pmc/article…
1
13
7 Jan 2022
Delighted to have co-hosted the @NIH workshop on 'Innate Immunity During #SARSCoV2 and #COVID19' w/ @Baric_Lab & Jenny Ting @UNC Insightful talks by 21 speakers and excellent science! Complement modulation and C3 targeting w/ #compstatins was discussed by @dmastellos @NIAIDNews
1
2
11
10 Sep 2021
The long history of compstatins in this space starts back in 2006 when analog 4(1MeW)7W (Cp05) was licensed by the University of Pennsylvania to Potentia (now Apellis) for clinical development in both dry and neovascular AMD See also this video for more: ophthalmologyweb.com/Videos/…
1
2
10 Sep 2021
Great news for #C3_therapeutics in a prevalent ocular disease with no approved therapy! Next-generation #compstatins with prolonged ocular residence & retinal tissue distribution are being developed for ocular diseases such as #GA #dryAMD See this paper: pubmed.ncbi.nlm.nih.gov/3222…
10 Sep 2021
A game-changing development in the #ComplementTherapeutics field! #Compstatin therapeutic #APL-2 met its primary endpoint in a Ph III trial in #GA #dryAMD. investors.apellis.com/news-r… See analysis by Umer Raffat and Jonnathan Miller below.
2
9
27 Jul 2021
We greatly appreciate @NIH's support, our "Gold" sponsor since 1990s, which made the development of #compstatins possible. Stay tuned as the compstatin family grows.
3
13
19 Mar 2021
Initial PoC for the broader therapeutic effect of both PEGylated and umodified compstatins on intravascular and C3-mediated extravascular hemolysis in PNH was reported in our 2014 @BloodJournal study pubmed.ncbi.nlm.nih.gov/2449…
19 Mar 2021
Thrilled that a #C3 therapeutic based on #compstatin discovered in our lab at Penn, shows impressive clinical results in comparison to #eculizumab and gets close to approval, validating the broader efficacy of #C3 vs #C5 inhibition in PNH nejm.org/doi/full/10.1056/NE…
2
4
7 Jun 2020
Complement C3 as a Target of Host Modulation in #Periodontitis: Following validation in NHP models of periodontal #inflammation, C3 inhibition moves to the bedside #complementbiology #oralcavity #dysbiosis #therapeutics #compstatins #AMY101 link.springer.com/chapter/10…
1
2
5
7 Jan 2020
A huge milestone for C3-targeted therapy that vindicates the science we invested behind the discovery of compstatins
Proud that a 2nd generation #compstatin analog has shown efficacy and superiority over Soliris in PNH patients"
This is exciting news for complement therapeutics!
7 Jan 2020
We are excited to share positive top-line results from our Phase 3 PEGASUS trial evaluating pegcetacoplan (APL-2), an investigational targeted C3 therapy, in adults with paroxysmal nocturnal hemoglobinuria (PNH). Read more here: investors.apellis.com/news-r… #PNH #raredisease
2
9
22
19 Jul 2019
Our review on the clinical promise of next-generation #complement #therapeutics is now published in @NatRevDrugDisc Real pleasure developing this story with Dan #Ricklin @UniBasel and the 'father' of #compstatins Prof John Lambris @LambrisLab @PennMedicine nature.com/articles/s41573-0…
5
12
17
14 Jun 2019
Worth checking out in @FrontImmunol: Anti-complement treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for proximal complement inhibition? #PNH #eculizumab #C3inhibitors #compstatins #FD #FB #complement_therapeutics #clinicalTrials frontiersin.org/article/10.3…
2
6
12 Mar 2019
Oral dysbiotic inflammation and #periodontal_disease in the crosshairs of #complement_therapeutics #C3 #compstatins #periodontitis #complementbiology frontiersin.org/article/10.3…
1
2